Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia

  2. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)
  3. Drug

    Plantago seed

    go.drugbank.com/drugs/DB11097
    ApprovedInvestigational

    It is found in some laxatives for treating occasional constipation and restoring regularity in bowel movements. … Its potential benefit in maintaining remission in ulcerative colitis has been studied [A27156].

    Mixtures: Konsyl Overnight Relief Senna Prompt
  4. Drug

    Magnesium oxide

    go.drugbank.com/drugs/DB01377
    ApprovedInvestigational

    Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. … It is used as an antacid and mild laxative and has many nonmedicinal uses.

    Mixtures: Cal-mag Plus K, Mn and Zn Caplets, Virt-Pn
  5. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

  6. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene. … Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

  7. Drug

    Relebactam

    go.drugbank.com/drugs/DB12377
    ApprovedInvestigational

    [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568] … infections in adults.

  8. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014.

    Synonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
  9. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  10. Drug

    Neon

    go.drugbank.com/drugs/DB11589
    Approved

    Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test. … It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.